Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Famous Investors
Top fund manager names 12 ASX shares for a recession proof portfolio
Share Market News
5 quality shares I'd like to buy in 2019
⏸️ ASX Shares
Where to invest $10,000 in All Ords shares this week
⏸️ ASX Shares
3 top ASX healthcare shares to buy in January
Share Gainers
Healius share price storms 11% higher on takeover news
Share Market News
5 shares to profit from a weaker Australian dollar in 2019
⏸️ ASX Shares
Should you buy Woolworths and two other ASX 100 shares?
⏸️ ASX Shares
Should you buy CSL shares and 2 other blue chips in 2019?
⏸️ Investing
8 companies to profit from a falling Australian dollar in 2019
Best Shares
Is the CSL Limited share price a buy?
⏸️ ASX Shares
3 ASX 200 shares to buy in 2019
Defensive Shares
How you can retire rich with these 3 ASX shares
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
